梅州润百颜玻尿酸(梅州做人流大概多少钱) (今日更新中)

It’s two weeks after Election Day, and President Donald Trump still refuses to concede that he lost the battle for the White House. Recounts underway are not expected to change the result. Democrat Joe Biden captured enough electoral votes to become the next President of the United States at noon on Jan 20.But what if Donald Trump refuses to leave the White House and keeps fighting?Seem far-fetched? Perhaps. But Monday morning, Trump tweeted, “I won the election!” And then, a little later, “The Radical Left Democrats, working with their partner, the Fake News Media, are trying to STEAL this Election. We won’t let them!” The Radical Left Democrats, working with their partner, the Fake News Media, are trying to STEAL this Election. We won’t let them!— Donald J. Trump (@realDonaldTrump) November 16, 2020 So, what may have once been unthinkable seems like a valid question to ask.PIX11 put the question to five leading election law scholars. What would happen if President Trump refused to leave, assuming the electoral votes cast on Electoral College Day (Dec. 14) go as expected and Joe Biden gets more than half the 538 available.“The important thing is not whether he is physically in the White House,” said Michael Dimino of Widener University Commonwealth Law School in Harrisburg, PA. “The important thing is who is permitted to exercise the powers of the presidency. The Constitution establishes a procedure for deciding that question.”That means Donald Trump no longer would have any authority.Professor Justin Levitt of Loyola Law School in Los Angeles told us, “The states will certify their results, the electors will cast their votes, Congress will count those votes … and then we’ve got a new President. And at noon on the 20th. … the only way that Donald Trump will be permitted on White House grounds is if he’s invited.”Richard Briffault, an authority on election law at Columbia Law School put it this way, “I also assume that at noon on January 20, he becomes a trespasser and possibly a security risk and could be removed.”Presumably, any forced removal would be handled by the same agency that protected President Trump during his term, the Secret Service.Rebecca Green, the co-director of the Election Law Program at William & Mary Law School, described what the new president could do to resolve any problem.“If Joe Biden is duly elected president and Trump refuses to leave the White House, Biden will order that Trump be escorted from White House grounds,” Green said.Another expert, whom we’re not naming because the professor is under contract as an election analyst with another media outlet, agreed that if Donald Trump stays in the White House, he’d be a trespasser and “he’d be escorted out if it came to that.”"Nobody can retain the powers of the presidency by refusing to leave,” Professor Dimono summed up. He underscored that the country is a nation of law. “It is the votes of the electors -- as counted by Congress -- that determine who can exercise the powers of the presidency," Dimono said.So, one way or the other, Donald Trump would have to vacate the premises. This story was first reported by Allen Levine at PIX11 in New York, New York. 3230

INDIANAPOLIS — A new drug from Eli Lilly and Company to help hospitalized COVID-19 patients requiring oxygen has received emergency use authorization from the U.S. Food and Drug Administration.Barivitinib, which is used in combination with remdesivir, can be given to both adult and pediatric patients two years old and older who are suspected to have or have a confirmed case of COVID-19 and need supplemental oxygen, invasive mechanical ventilation, or extracorporeal membrane oxygenation. "Since the start of the COVID-19 pandemic, Lilly has been committed to finding potential treatments to help people around the world who've been impacted by this virus," David A. Ricks, Lilly chairman and CEO, said in a press release. "Today's FDA action for baricitinib marks the second Lilly therapy to be granted an EUA, in addition to the recent neutralizing antibody EUA for high-risk non-hospitalized patients, increasing the number of treatment options for COVID-19 patients at different stages of the disease. This is an important milestone for hospitalized patients on oxygen, as baricitinib may help speed their recovery."Patients treated with the drug in combination with remdesivir had a "significant reduction in median time to recovery," according to the press release.Baricitinib has not been approved by the FDA to treat COVID-19 and studies are still underway in clinical trials, according to the press release.Eli Lilly and Company is working with healthcare systems and governments to facilitate patient access to the drug."With respect to supply, Lilly remains confident in being able to meet the needs of patients under the EUA in the U.S., as well as for existing approved indications around the world," the press release read. To learn more about the drug, click here.Earlier this month, Eli Lilly and Company received an emergency use authorization for its experimental COVID-19 antibody treatment.This article was written by Andrew Smith for WRTV. 1984

INDIANAPOLIS — The U.S. Food and Drug Administration on Monday granted emergency use authorization to Eli Lilly and Company's experimental COVID-19 antibody treatment bamlanivimab.According to a statement from the company, the drug is authorized for the treatment of mild to moderate COVID-19 in adults and pediatric patients 12 years and older with a positive COVID-19 test who are at high risk for progressing to severe COVID-19 and/or hospitalization. Lilly said in a statement the drug should be administered as soon as possible after a positive COVID-19 test and within 10 days of symptom onset. The authorization allows for the distribution and emergency use of bamlanivimab, which is administered via a single intravenous infusion."This emergency authorization allows us to make bamlanivimab available as a COVID-19 treatment for recently diagnosed, high-risk patients — adding a valuable tool for doctors fighting the now-increasing burden of this global pandemic," David A. Ricks, Lilly's chairman and CEO, said. "The rapid development and availability of bamlanivimab could not have been achieved without the relentless work of our Lilly team, collaboration across the industry and the urgent work being done by the government to ensure appropriate allocation to patients who need it the most."The emergency use authorization is based on data from BLAZE-1, a randomized, double-blind, placebo-controlled Phase 2 study in patients with recently diagnosed mild to moderate COVID-19 in the outpatient setting. Patients treated with the drug showed reduced viral load and rates of symptoms and hospitalization, Lilly said in the statement. Infusion reactions and other allergic hypersensitivity events have been reported, Lilly said. The emergency use authorization includes a warning for hypersensitivity including anaphylaxis and infusion-related reactions.Lilly said the drug is not authorized for use in patients who are hospitalized due to COVID-19 or who require oxygen therapy due to COVID-19 or who require an increase in baseline oxygen flow rate due to COVID-19 in those on chronic oxygen therapy due to underlying non-COVID-19 related comorbidity."The BLAZE-1 data show bamlanivimab, when given early in the disease course, may help patients clear the virus and reduce COVID-related hospitalizations, supporting our belief that neutralizing antibodies can be an important therapeutic option for patients fighting this virus," Daniel Skovronsky, M.D., Ph.D., Lilly's chief scientific officer and president of Lilly Research Laboratories, said. "We're proud of the speed with which we have been able to bring patients this therapy specifically designed to treat COVID-19. We thank those who have contributed to this medical advancement, particularly the clinical trial investigators and participants around the country." This article was written by Bob Blake for WRTV. 2906

VIRGINIA BEACH, Va. - The Griswold family station wagon with an uprooted tree and Cousin Eddie's rusted-out RV are two iconic items from the movie "National Lampoon's Christmas Vacation.""It is one of the most nostalgic Christmas movies of all time," said Mike Palacious, creative consultant with Lawyer Garage, a rare car collectible company.You can see the decked-out replicas for yourself in Virginia Beach starting this week. "2020 has been a rough year for everybody, so we tried to figure out a way to come up with holiday cheer," said Palacious.The holiday display also includes Clark Griswold on the roof putting up thousands of twinkling lights and cast cutouts for all to enjoy."This is a free, COVID-friendly drive-thru," he said.The display is just a taste of Lawyer Garage's secret collection. Monday, they allowed News 3 to get a glimpse of the rare finds. Red carpet lines the secret location, lined with bizarre rides and hard-to-find items.They include things like a restored 1959 Chevy Apache Good Humor ice cream truck, the original Batmobile, the Joker's motorcycle, a life-size Tonka Truck and the Mystery Machine, to name a few. There are more than 60 collectibles that make up Lawyer Garage’s unbelievable display."Cars are a language for everyone everyone can relate to a certain type of car, whether it be from childhood or a TV car you grew up watching. Cars are an international language," he said.But the language this year is Christmas cheer – in a time we all need it the most."Having all these out here is bringing so much joy and happiness to everyone," said Palacious.While the display is sure to bring joy, those at Lawyer Garage are all about charity. Kids can bring their wish list to Santa's mailbox, and the company will pick three families they'll buy gifts for this year. This article was written by Chelsea Donovan for WTKR. 1889

Governor Greg Abbott has issued an executive order requiring all Texans to wear a face covering over the nose and mouth in public spaces. The order applies to counties with 20 or more positive COVID-19 cases, with few exceptions. The governor also issued a proclamation giving mayors and county judges the ability to impose restrictions on some outdoor gatherings over 10 people and making it mandatory that, with certain exceptions, people cannot be in groups later than 10 and must maintain six feet of social distancing from others. "Wearing a face covering in public is proven to be one of the most effective ways we have to slow the spread of COVID-19,” said Governor Abbott. “We have the ability to keep businesses open and move our economy forward so that Texans can continue to earn a paycheck, but it requires each of us to do our part to protect one another—and that means wearing a face covering in public spaces. Likewise, large gatherings are a clear contributor to the rise in COVID-19 cases. Restricting the size of groups gatherings will strengthen Texas’ ability to corral this virus and keep Texans safe. We all have a responsibility to slow the spread of COVID-19 and keep our communities safe. If Texans commit to wearing face coverings in public spaces and follow the best health and safety practices, we can both slow the spread of COVID-19 and keep Texas open for business. I urge all Texans to wear a face covering in public, not just for their own health, but for the health of their families, friends, and for all our fellow Texans.”The governer released a new video message to coincide with the executive order, encouraging Texans to do their part to mitigate the spread of COVID-19 and keep communities safe. To view the video, visit the top of this article. This article was written by Sydney Isenberg for KXXV. 1863

来源：资阳报